Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 Nov;35(6):401–411. doi: 10.1007/BF01789019

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2

Shoshana Morecki 1,✉, Shoshana Revel-Vilk 1, Corinne Nabet 1, Marjorie Pick 1, Aliza Ackerstein 1, Arnon Nagler 1, Elizabeth Naparstek 1, Menahem Ben Shahar 1, Shimon Slavin 1
PMCID: PMC11038767  PMID: 1394343

Abstract

Immunological parameters were evaluated in patients treated with cytokine-mediated immunotherapy (CMI) consisting of low doses of recombinant human interferon α2a (rIFNα) and recombinant human interleukin-2 (rIL-2) administered either concomitantly or sequentially by subcutaneous self-injections in an outpatient setting. Twenty-six patients with hematological malignancies and 2 metastatic melanoma patients in a progressive stage were enrolled in this clinical trial. Of the 26 patients, 24 were at a stage of minimal residual disease, including 14 patients who had received autologous bone marrow transplantation (ABMT) 2–5 months previously, 7 chronic myelogenous leukemia (CML) and 3 acute myeloid leukemia (AML) patients. Two patients (1 CML and 1 mult. myeloma) were treated at a stage of progressive disease. Non-MHC-restricted cytotoxicity directed against natural-killer(NK)-resistant (Daudi) and NK-sensitive (K562) target cells was assessed before, during and after CMI, either in fresh peripheral blood samples (spontaneous activity) or after in vitro rIL-2 activation (induced activity). Spontaneous killing activity was low prior to treatment, but increased upon termination of treatment in 10/15 evaluated cycels. rIL-2-activated cytotoxicity in vitro was markedly elevated in 8/12 and 6/8 patients after one and two cycles, respectively, of sequential treatment, as well as in 3/8 CML and 5/6 patients after one and two cycles, respectively, of concomitant treatment Activation of the T cell mitogenic response was demonstrated in 6/9 patients after concomitant CMI, while no such effect was observed throughout a sequential treatment in lymphoma and leukemia patients after ABMT. Although a direct correlation between immune stimulation and the in vivo antitumor response cannot yet be determined, our clinical observations support a beneficial therapeutic effect in a substantial number of patients. These results indicated that the ambulatory CMI protocol of rIL-2 and rIFNα could stimulate the host defense immune system and may be helpful in mediating the in vivo antitumor response in patients with minimal residual disease.

Key words: Cytokine therapy, Hematological malignancies, Interferon α2a, Interleukin-2

References

  • 1.Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 1988;71:709. [PubMed] [Google Scholar]
  • 2.Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet. 1990;335:1509. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  • 3.Blaise D, Viens P, Olive D, Stoppa AM, Gabert J, Pourreau CN, Attal M, Gaspard MH, Mannoni P, Jasmin C, Palmer P, Franks C, Michel G, Mawas C, Baume D, Philips T, Maraninchi D. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur Cytokine Met. 1991;2:121. [PubMed] [Google Scholar]
  • 4.Borzy MS, Ridgway D. Prolonged defects of interleukin-2 production, responsiveness and receptor expression in patients with acute lymphoblastic leukemia. Blood. 1989;73:1608. [PubMed] [Google Scholar]
  • 5.Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21(Suppl 97):77. [PubMed] [Google Scholar]
  • 6.Brund MJ, Tarnowski D, Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer. 1986;37:787. doi: 10.1002/ijc.2910370522. [DOI] [PubMed] [Google Scholar]
  • 7.Chang WC, Fujimiya Y, Casteel N, Pattengale P. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia: III. Defective interleukin-2 production by T-helper and natural killer cells. Int J Cancer. 1989;43:591. doi: 10.1002/ijc.2910430410. [DOI] [PubMed] [Google Scholar]
  • 8.Dabholkar M, Advani S, Tatake R, Gangal S. Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission. Leukemia Res. 1986;10:203. doi: 10.1016/0145-2126(86)90043-3. [DOI] [PubMed] [Google Scholar]
  • 9.Dabholkar M, Tatake R, Amin K, Advani S, Gangal S. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin 2 in chronic myeloid leukemia patients in remission. Oncology. 1989;46:123. doi: 10.1159/000226698. [DOI] [PubMed] [Google Scholar]
  • 10.Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DDH, Doroshow JH, Rayner AA, Hawkins M, Atkins M. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989;7:477. doi: 10.1200/JCO.1989.7.4.477. [DOI] [PubMed] [Google Scholar]
  • 11.Fidler IJ, Heicappell R, Saiki I, Grutter G, Horsberger MA, Nuesch J. Direct anti-proliferative effects of recombinant human interferon a B/D hybrids on human tumor cell lines. Cancer Res. 1987;47:2020. [PubMed] [Google Scholar]
  • 12.Foa R, Guarini A, Tos AG, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation. Cancer Res. 1991;51:964. [PubMed] [Google Scholar]
  • 13.Fujimiya Y, Bakke A, Chang WC, Linker-Isreli M, Udis B, Horowitz D, Pattengale PK. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia: I. Analysis of the defect using monoclonal antibodies HNK-1 (Leu-7) and B73.1. Int J Cancer. 1986;37:639. doi: 10.1002/ijc.2910370502. [DOI] [PubMed] [Google Scholar]
  • 14.Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber C. Effects of human recombinant a2 arg-interferon and g-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res. 1985;45:2957. [PubMed] [Google Scholar]
  • 15.Gottlieb DJ, Prentic HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemoradiotherapy for hematological malignancy. Blood. 1989;74:2335. [PubMed] [Google Scholar]
  • 16.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Malaspinia HC, O'Reilly RJ, Keever CA. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1990;75:2250. [PubMed] [Google Scholar]
  • 18.Herberman RB, Ortaldo JR. Natural killer cells: their role in defenses against disease. Science. 1981;214:24. doi: 10.1126/science.7025208. [DOI] [PubMed] [Google Scholar]
  • 19.Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lotzova E, Bolhuis R, Golub S, Lanier LL, Phillips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A. Lymphokine-activated killer cell activity. Immunol Today. 1987;8:178. doi: 10.1016/0167-5699(87)90035-1. [DOI] [PubMed] [Google Scholar]
  • 20.Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J. Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood. 1986;67:722. [PubMed] [Google Scholar]
  • 21.Hersey P, Bolhuis R. “Nonspecific” MHC-unrestricted killer cells and their receptors. Immunol Today. 1987;8:233. doi: 10.1016/0167-5699(87)90173-3. [DOI] [PubMed] [Google Scholar]
  • 22.Heslop HE, Gottlieb DJ, Bianchi AC, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989;74:1374. [PubMed] [Google Scholar]
  • 23.Higuchi CM, Thompson JA, Cox T, Lindgren CG, Bruckner CD, Fefer A. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res. 1989;49:5509. [PubMed] [Google Scholar]
  • 24.Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol. 1990;8:1657. doi: 10.1200/JCO.1990.8.10.1657. [DOI] [PubMed] [Google Scholar]
  • 25.Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL. A phase I study of recombinant interleukin 2 plus recombinant b-interferon. Cancer Res. 1988;48:3875. [PubMed] [Google Scholar]
  • 26.Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2A in cancer patients: a phase I study. J Clin Oncol. 1989;7:1726. doi: 10.1200/JCO.1989.7.11.1726. [DOI] [PubMed] [Google Scholar]
  • 27.Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 1987;138:2718. [PubMed] [Google Scholar]
  • 28.Mackinnon S, Hows JM, Goldman JM. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood. 1990;76:2037. [PubMed] [Google Scholar]
  • 29.Mehta B, Advani S, Nadkarni J. Non-Hodgkin's lymphoma: natural cell-mediated cytotoxicity correlated with histological classification and prognosis. Oncology. 1989;46:323. doi: 10.1159/000226741. [DOI] [PubMed] [Google Scholar]
  • 30.Morecki S, Nabet C, Ackerstein A, Schlesinger M, Slavin S. The effect of in-vitro T lymphocyte depletion on generation of IL-2 activated cytotoxic cells. Bone Marrow Transplant. 1991;7:269. [PubMed] [Google Scholar]
  • 31.Nagler A, Greenberg PL, Lanier LL, Phillips JH. The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors. J Exp Med. 1988;168:47. doi: 10.1084/jem.168.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nagler A, Ackerstein A, Naparstek E, Ben-Neriah S, Barak V, Slavin S (1991) Concomitant treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-a2a (in press) [DOI] [PubMed]
  • 33.Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood. 1986;68:938. [PubMed] [Google Scholar]
  • 34.Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukemia after in vivo treatment with interferon a (Wellferon) Cancer Immunol Immunother. 1989;29:63. doi: 10.1007/BF00199918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Petrie A. Lecture notes on medical statistics. London: Blackwell; 1978. Linear regression and correlation; p. 102. [Google Scholar]
  • 36.Phillips JH, Genlo BT, Myers WW, Rayner AA, Lanier LL. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol. 1987;5:1933. doi: 10.1200/JCO.1987.5.12.1933. [DOI] [PubMed] [Google Scholar]
  • 37.Pillai MR, Balaram P, Padmanabhan TK, Abraham T, Nair K. Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy. Acta Oncol. 1989;28:39. doi: 10.3109/02841868909111179. [DOI] [PubMed] [Google Scholar]
  • 38.Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310:15. doi: 10.1056/NEJM198401053100104. [DOI] [PubMed] [Google Scholar]
  • 39.Rajaram N, Tatake RJ, Advani SH, Naik SL, Gangal SG. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunol Immunother. 1990;31:44. doi: 10.1007/BF01742494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rettie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Brenner MK. Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation but not after chemotherapy. Blood. 1989;73:1351. [PubMed] [Google Scholar]
  • 41.Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421. [PubMed] [Google Scholar]
  • 42.Rosenberg SA. Immunotherapy of cancer using interleukin 2. Immunol Today. 1988;9:58. doi: 10.1016/0167-5699(88)91261-3. [DOI] [PubMed] [Google Scholar]
  • 43.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 44.Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan MW, Siepp CA, White DE. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  • 46.Roth MS, Bunn PA, Foon KA. Interferon therapy for lymphoproliferative disorders. Cancer Treat Res. 1988;38:231. doi: 10.1007/978-1-4613-1713-5_7. [DOI] [PubMed] [Google Scholar]
  • 47.Smith KA. Interleukin-2: inception, impact and implication. Science. 1988;240:1169. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  • 48.Soiffer R, Murray C, Cochran K, Ish C, Wang E, Ritz J (1990) Selective expansion of NK cells in patients given low dose recombinant IL-2 after BMT (abstract). Blood 76 [Suppl 1]: 220a
  • 49.Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  • 50.Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987;69:1280. [PubMed] [Google Scholar]
  • 51.Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990;50:185. [PubMed] [Google Scholar]
  • 52.Voogt PJ, Falkenburg JHF, Fibbe WE, Veenhof WFJ, Hamilton M, Van Krimpen BA, Bolhuis RLH. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD−, T cell receptor+/CD3+ and T cell receptor ab+/CD3 lymphocytes. J Immunol. 1989;142:1774. [PubMed] [Google Scholar]
  • 53.Yabuhara A, Kawai H. A recycling defect as characteristic of natural killer cells in childhood acute lymphoblastic leukemia. Pediatr Res. 1990;28:572. doi: 10.1203/00006450-199012000-00004. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES